Valbenazine Eases Chorea in Trial; FDA Submission Expected Next Year

Valbenazine Eases Chorea in Trial; FDA Submission Expected Next Year

314166

Valbenazine Eases Chorea in Trial; FDA Submission Expected Next Year

Treatment with valbenazine significantly lessened chorea — a motor symptom characterized by jerky, unpredictable, and involuntary movements — in people with Huntington’s disease in the Phase 3 clinical trial KINECT-HD, according to an announcement from the therapy’s developer, Neurocrine Biosciences. Neurocrine now is planning to submit an application next year asking the U.S. Food and Drug Administration (FDA) to approve valbenazine to treat Huntington’s-associated chorea. “The positive results of the KINECT-HD study move us closer…

You must be logged in to read/download the full post.